BRCA1 and neoplasm: They also showed a decrease in breast epithelial cell proliferation in three premenopausal women treated with denosumab, and a significant increase in basal-like tumor latency in mammary hyperplasia among Brca1 deficient mice (that also develop) treated with a RANKL inhibitor (15).